CADM2 and breast cancer: The recently experimentally validated cancer types for this lncRNA included breast cancer [26] (using qRT-PCR), gastric cancer (by constructing a potential ceRNA network using bioinformatics tools and then validating the ADAMTS9-AS2/miR-372/CADM2 axis using qRT-PCR and dual luciferase reporter assay) [75], tongue squamous cell carcinoma (constructing ADAMTS9-AS2/miR-600/EZH2 ceRNA network) [79] and others.